Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Castle Biosciences (Nasdaq: CSTL) said the New York State Department of Health approved its AdvanceAD-Tx™ gene expression profile test for patients aged 12+ with moderate-to-severe atopic dermatitis. The assay is intended to classify patients into JAK inhibitor responder or Th2 molecular profiles to guide systemic therapy selection.
How this was made
The 30-second read
Why it matters
NYSDOH assay approval via the Clinical Laboratory Evaluation Program reduces regulatory friction for offering the test in New York and completes Castle’s stated approval coverage across its dermatology and ophthalmology portfolios and other listed tests.
Market read
A concrete regulatory approval for a commercial diagnostic test is a tangible commercialization step that can drive incremental ordering and investor sentiment.
What to watch
Adoption depends on clinician ordering behavior, reimbursement dynamics, and whether the test’s clinical utility translates into reduced switching; the release provides no revenue or volume guidance.
Background
AdvanceAD-Tx is a non-invasive gene expression profile test that classifies atopic dermatitis patients into JAK inhibitor responder vs Th2 molecular profiles to guide systemic therapy selection.
Ticker impact
Castle Biosciences received NYSDOH assay approval for its AdvanceAD-Tx test, expanding access for moderate-to-severe atopic dermatitis patients.
Near-term upside bias for CSTL on improved commercialization prospects in a regulated jurisdiction, with follow-through depending on broader payer/provider uptake.
The article is a first-time regulatory approval announcement tied to a specific product (AdvanceAD-Tx) and jurisdiction (NYSDOH Clinical Laboratory Evaluation Program), which typically reduces friction for ordering and reimbursement workflows.
Market effects
Supports the broader narrative that molecular diagnostics for dermatology are gaining regulatory traction, potentially improving investor appetite for similar CLIA/LDT pathways.
Improves test accessibility specifically in New York, which can translate into incremental volume and referenceability for providers operating in the state.
Moderate, as NY-specific approval may not directly change international commercialization but can be used as evidence of regulatory rigor.
Counterpoint
The approval is jurisdiction-specific and does not guarantee payer coverage or national scale adoption, so the financial impact may be limited versus market expectations.
Key entities
- companyCastle Biosciences
Nasdaq-listed diagnostics company announcing NYSDOH assay approval for AdvanceAD-Tx.
- productAdvanceAD-Tx
Non-invasive gene expression profile test for guiding systemic therapy selection in moderate-to-severe atopic dermatitis.
- regulatorNew York State Department of Health (NYSDOH)
Approved the assay under its Clinical Laboratory Evaluation Program, enabling easier patient access in New York.
